©The Author(s) 2026.
World J Methodol. Mar 20, 2026; 16(1): 108646
Published online Mar 20, 2026. doi: 10.5662/wjm.v16.i1.108646
Published online Mar 20, 2026. doi: 10.5662/wjm.v16.i1.108646
Table 3 Comparison between phage therapy and antibiotics
| Feature | Phage therapy | Antibiotics |
| Mechanism of action | Targets and infects specific bacteria, leading to their lysis | Interferes with essential bacterial processes like cell wall or protein synthesis |
| Host specificity | Highly specific—usually affects only certain strains and species | Broad spectrum—may act on various bacterial species |
| Resistance development | Bacteria can develop resistance, but phages may co-evolve | Resistance is a growing issue, and development of new antibiotics is slow |
| Impact on microbiota | Minimal disruption to beneficial microbiota | Can disrupt gut flora, leading to dysbiosis or secondary infections like Clostridioides difficile infection |
| Replication in host | Multiplies at the infection site if host bacteria are present | Does not self-replicate; efficacy depends on dosage |
| Immunogenicity | May trigger immune response, especially with repeated use | Less likely to elicit strong immune reactions |
| Production and customization | Can be tailored to target specific pathogens | Mass-produced with fixed formulations |
| Environmental impact | Generally considered eco-friendly | Overuse can contribute to antibiotic resistance and gut dysbiosis |
- Citation: Mishra A, Juneja D. Decolonizing the gut from multidrug-resistant bacteria: Current strategies and future perspectives. World J Methodol 2026; 16(1): 108646
- URL: https://www.wjgnet.com/2222-0682/full/v16/i1/108646.htm
- DOI: https://dx.doi.org/10.5662/wjm.v16.i1.108646